{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Artiva Biotherapeutics, Inc."},"Symbol":{"label":"Symbol","value":"ARTV"},"Address":{"label":"Address","value":"5505 MOREHOUSE DRIVE,DRIVE, SAN DIEGO, California, 92121, United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Artiva Biotherapeutics is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patients own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patients treatment location, making them what we believe to be off-the-shelf. Our lead product candidate, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in an ongoing Phase 1/1b trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications."},"CompanyUrl":{"label":"Company Url","value":"www.artivabio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Christopher Horan","title":"Chief Technical Operations Officer"},{"name":"Fred Aslan","title":"President, Chief Executive Officer & Director"},{"name":"Jennifer Kinsbruner Bush","title":"Chief Operating Officer"},{"name":"John K. C. Lim","title":"Vice President-Clinical Operations"},{"name":"Thorsten Graef","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}